| RESEARCH ARTICLE |
|
| Year : 2014 | Volume
: 3
| Issue : 2 | Page : 179-183 |
|
|
Development and validation of a new method for determination of topiramate in bulk and pharmaceutical formulation using high performance liquid chromatography-UV detection after pre-column derivatization
Mohammad Bagher Majnooni1, Ronak Jalili2, Bahareh Mohammadi2, Sayed Shahram Miraghaee2, Mohammad Taher bahrami2, Sajad Fakhri2, Gholamreza Bahrami3
1 Department of Pharmacology and Toxicology, Faculty of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, Iran
2 Medical Biology Research Center, Medical School, Kermanshah University of Medical Sciences, Kermanshah, Iran
3 Department of Pharmacology and Toxicology, Faculty of Pharmacy, Kermanshah University of Medical Sciences; Medical Biology Research Center, Medical School, Kermanshah University of Medical Sciences, Kermanshah, Iran
Correspondence Address:
Ronak Jalili
Medical Biology Research Center, Medical School, Kermanshah University of Medical Sciences, Kermanshah
Iran
 Source of Support: None, Conflict of Interest: None  | Check |
|
|
|
In published high performance liquid chromatographic (HPLC) methods for analysis of topiramate (TPM) in pharmaceutical dosage forms and raw materials Refractive Index Detector (RID) has been used which is not available in many laboratories and has low sensitivity. We described a new, sensitive and simple HPLC method for determination of topiramate in pharmaceutical forms and In-virto dissolution studies which avoids the use of RID detector. The method is based on derivatization of topiramate and an internal standard by reaction with 4-chloro-7-nitrobenzofurazan (NBD-CL), and reverse-phase chromatography using phenyl column and spectrophotometer detection at 264 nm. A mixture of phosphate buffer (0.05 M) containing triethylamine (0.1% V/V; pH=2.3) and methanol (28:72, V/V) at a flow rate of 2.2 ml/min was used as mobile phase. The analysis performance was studied and the method was shown to be selective and linear for determination of topiramate in pharmaceutical forms and dissolution studies.
|
|
|
|
| [PDF]* |
|
 |
|
